Quick Answer
Tango Therapeutics, Inc. reported Common Stock Shares Outstanding of 135.94 million shares for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +26.2% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: 5.63 million shares | Q1 2021: 5.67 million shares | Q2 2021: 5.74 million shares | Q3 2021: 87.54 million shares | Q1 2022: 87.71 million shares | Q2 2022: 88.00 million shares | Q3 2022: 88.07 million shares | Q1 2023: 88.21 million shares | Q2 2023: 88.46 million shares | Q3 2023: 101.85 million shares | Q1 2024: 106.73 million shares | Q2 2024: 107.04 million shares | Q3 2024: 107.41 million shares | Q1 2025: 108.11 million shares | Q2 2025: 110.87 million shares | Q3 2025: 111.57 million shares.
- Over the full 7 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 236.7%.
- Historical annual values: Fiscal year 2025: 135.94 million shares | Fiscal year 2024: 107.73 million shares | Fiscal year 2023: 102.20 million shares | Fiscal year 2022: 88.18 million shares | Fiscal year 2021: 87.60 million shares | Fiscal year 2021: 87.47 million shares | Fiscal year 2020: 40.37 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: